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a b s t r a c t
Microglia are the resident phagocytic cells of the central nervous system. During brain development
they are also imperative for apoptosis of excessive neurons, synaptic pruning, phagocytosis of debris and
maintaining brain homeostasis. Brain damage results in a fast and dynamicmicroglia reaction, which can
inﬂuence the extent and distribution of subsequent neuronal dysfunction. As a consequence, microgliaeywords:
erinatal brain injury
euroinﬂammation
responses can promote tissue protection and repair following brain injury, or become detrimental for
the tissue integrity and functionality. In this review, we will describe microglia responses in the human
developing brain in association with injury, with particular focus on the preterm infant. We also explore
microglia responses and mechanisms of microglia toxicity in animal models of preterm white matter
injury and in vitro primary microglia cell culture experiments.
© 2014 The Authors. Published by Elsevier Inc. All rights reserved.. Introduction
Microglia are the resident mononucleated phagocytic cells of
he central nervous system (CNS) that in their dormant state con-
tantly survey their environment with their extensive processes
see review [1]). Microglia lineage has long been debated, how-
ver, recent studies have demonstrated that microglia originate
rom primitive macrophages in the embryonic yolk sac, prior
o hematopoiesis [2]. Upon the formation of embryonic circula-
ion, microglia progenitors enter the neuroepithelium and become
stablished in the brain. Hence, microglia develop independently
rom hematopoiesis and hematopoietic stem cells [3] and inter-
stingly it has been shown that increased activation/proliferation
f microglia is in fact due to local expansion of resident microglial
ells as opposed to recruitment of bloodmonocytes [4,5]. Although,
icroglia are largely known as the resident immune cells of the
NS, they are also imperative in normal development of the brain.
hey are involved in apoptosis of excessive neurons, synaptic prun-
ng, phagocytosis of debris and maintaining brain homeostasis
1,6,7].
Hypoxia–ischemia [8,9] and intra-cerebral administration of
xcitotoxins such as N-methyl-d-aspartate (NMDA) [10] or
∗ Corresponding author. Tel.: +46 317863498.
E-mail addresses: carina.mallard@neuro.gu.se, carina.mallard@fysiologi.gu.se
C. Mallard).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.reprotox.2014.04.002
890-6238/© 2014 The Authors. Published by Elsevier Inc. All rights reserved.ibotenate [11] result in a fast and robust microglia reaction in the
developing brain. Neuroinﬂammation is a dynamic process that
plays a key role in the pathogenesis of injury in the developing
brain and in response to inﬂammatory stimuli or tissue injury,
microglia secrete a wide range of soluble factors, such as cytokines,
substances with excitatory amino acid agonist properties, and glial
promoting factors thatmay inﬂuence theextent of subsequentneu-
ronal injury. As a consequence, microglia responses can promote
tissueprotectionand repair followingbrain injury, or becomedetri-
mental for the tissue integrity and functionality. In this review we
will describe microglia responses in the human developing brain
in association with injury, with particular focus on the preterm
infant. We will also consider microglia responses in animal models
of preterm white matter injury and the contribution of systemic
innate reactions to neuroinﬂammation. By reviewing in vitro pri-
mary microglia preparations, we explore mechanisms of microglia
toxicity.
2. Preterm brain injury
Despite advances in neonatal care there is still signiﬁcant
mortality and morbidity arising from injuries to the developing
brain with complications of prematurity [12]. Half of all surviv-
ing preterm infants born at or less than 25 gestational weeks,
show neurodevelopmental impairment at 30 months of age [13]
and at 6 years of age, approximately 40% have cognitive impair-
ment compared to their classroom peers [14]. Magnetic resonance
imaging (MRI) studies of infants born preterm have shown that
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erebral white matter injury is the predominant pathology of
rematurity [15]. However with recent advances in MRI tech-
iques and methodology, it has become clear that white matter
njury in the preterm brain is accompanied by abnormal develop-
ent of the cortical and deep gray matter regions [16–19]. This
omplex involvement of gray matter and white matter lesions,
hich are major determinants of neurologic outcome, is known
s “encephalopathy of prematurity”. The periventricular regions
re the most common site of preterm white matter injuries
ecognized on MRI, such as periventricular leukomalacia (PVL),
unctate lesions, diffuse excessive high signal intensity, all of
hich affect white matter development directly, whilst germi-
almatrix/intraventricular hemorrhage (GMH/IVH) has an indirect
ffect on the white matter [20]. Injury to the preterm white matter
s said to arise from infection/inﬂammation and hypoxia–ischemia,
hich could in turn leave premyelinating oligodendrocytes, sub-
late neurons, latemigrating-aminobutyric acid (GABA) neurons,
nd growing axonal trajectories vulnerable to injury [21]. Post-
ortem studies done over the past decade suggest that activated
icroglial cells may play a crucial role in mediating injury to the
reterm brain [22–24].
. Microglia in the developing human brain
In the developing human brain,microglial entry into the embry-
nic forebrain and cerebral cortex is evident as early as 4.5–5.5
estational weeks through the meninges, choroid plexus and ven-
ricles [25].Microglial penetration through thevascular component
as evident around 10 gestational weeks [26]. The large majority
f microglial inﬂux and distribution begins around 16 gestational
eeks as ramiﬁed cells, and they continue to differentiate and
ecomewidelydistributedas ramiﬁedandactivecellsupuntil close
o term age [27,28]. Clusters of transient “resident” populations of
moeboid microglia in the normal preterm brain are prevalent in
he periventricular crossroads regions of intersecting callosal, asso-
iative and thalamocortical axonal pathways in the white matter
24,29], and during mid to late gestation the cerebral white matter
xpress high levels of growth associated protein 43, which is asso-
iated with active axonal outgrowth [22]. This transient elevation
f active “resident” population of microglia in the preterm white
atter implies the involvement of microglia in the development
nd guidance of axonal projections, myelinogenesis and possibly
role in pruning overabundant axons and cells that have failed to
each their developmental destination [27,29,30]. It has been sug-
ested that this normal developmental increase in the “resident”
opulation ofmicroglia in the periventricular whitematter regions
f the preterm brain may be responsible for “priming” this region
or inﬂammatory injury [31].
. Preterm periventricular leukomalacia
One of the ﬁrst postmortem studies investigating the patho-
hysiology of preterm PVL demonstrated that injury associated
ith microglial and astroglial activation is not just contained to
he periventricular necrotic foci of the cystic lesion, but is evident
s widespread activation in the diffuse component of PVL in the
hite matter away from the lesion site [32]. Evidence of inﬂam-
atory cytokine involvement in preterm white matter injury was
eported by Kadhim and colleagues, who showed increased pro-
nﬂammatory cytokine expression (interleukin (IL)-1, IL-2 and
umor necrosis factor (TNF)-) in the white matter of preterm
VL brains [33,34]. Myelination abnormalities of PVL are believed
o be due to arrested maturation of premyelinating oligodendro-
ytes induced by nitrosative and oxidative mechanisms mediated
y microglial cells [32,35,36]. There are also neuronal componentsToxicology 48 (2014) 106–112 107
to the injury, including increase in gliosis and thalamic neuronal
loss (60%) together with signiﬁcant microglial activation [37]. We
demonstrated the expression of the innate immune receptor toll-
like receptor (TLR) 3 in both glia and neurons in conjunction with
preterm white matter injury [38]. A recent postmortem study
showed loss of granular neurons in the ventricular/subventricular,
periventricular and central white matter regions in preterm PVL
[39], which was suggested to be an important contributing fac-
tor in neurocognitive deﬁcits seen in preterm brain injury. Further,
investigation of the prefrontal cortex in autistic patients showed
that there was increased microglia-neuron spatial clustering [40].
However, whether the microglia are involved in neuronal protec-
tion and healing or if they are having a deleterious effect on the
neurons remains unclear. Nevertheless these ﬁnding are of par-
ticular interest, as long-term follow up studies of preterm infants
have shown that they are at an increased risk of neurocognitive dif-
ﬁculties as well as psychiatric illnesses including autistic spectrum
disorder [41,42].
With advances in neonatal intensive care, there has been a
decline in the incidence of classic PVL and non-cystic lesion/diffuse
white matter injury is now the predominant type of MRI-deﬁned
brain injury in the preterm cohort [43]. Postmortem investigations
of diffuse white matter injury show increased microglia activation
in both the lesion site and in the deeper white matter regions in
this population [44]. Although the diffusemicroglial activationwas
associated with preoligodendrocyte regeneration, these cells were
in an arrested state ofmaturation, similar to that seen in classic PVL,
resulting in a reduced pool of mature oligodendrocytes. In the very
preterm (26–31 gestational weeks) brain with diffuse injury, the
periventricular axonal crossroads region of white matter is charac-
terized by an enlarged microglia population and axonopathy [24].
Hypothetically, the increased microglial activation in the periven-
tricular crossroads regionmayhaveadetrimental effect ongrowing
axonal pathways in the white matter during early development.
5. Punctate white matter lesion
Whilst preterm punctate white matter lesions are quite com-
mon on serial MRI scans (evident in 22% of infants born less than
30 weeks gestational age), the lesions decrease in number by term
equivalent age [45]. Although the mortality rate of preterm infants
with punctate lesion is low, these infants still show reduced myeli-
nationandcortical folding at term.One isolatedpostmortemcaseof
preterm punctate white matter lesion (identiﬁed on postmortem
MRI) showed that the lesions corresponded to areas of vascular
congestion and inﬁltration of dense microglial activation [20].
6. Preterm germinal matrix/intraventricular heamorrhage
Preterm isolated GMH/IVH with no overt venous parenchymal
infarction (as evidenced by postmortem MRI), showed increased
microglial activation, cell apoptosis and axonal injury in the
periventricular white matter [23]. These results suggest that minor
isolated GMH in the preterm brain may still result in deleterious
effect on the adjacent white matter through microglial activation.
Microglial activation in the periventricular white matter increased
with increased severity of hemorrhagic injury, and in addition to
increased cell apoptosis and axonal injury, there was evidence
of increased TNF- expression whilst the expression of IL-10
remained unchanged [23,46]. These results suggest that the persis-
tent activation ofmicroglia in pretermbrainswith severeGMH/IVH
may be a contributing factor to injury through pro-inﬂammatory
mediators.
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. Animal models of fetal and neonatal white matter injury
In support of the clinical evidence discussed above, studies in
edium- to large-sized animals have frequently demonstrated a
ink between intrauterine infection/inﬂammation or fetal asphyxia
nd microglia activation in the developing brain. Pregnant New
ealand rabbits, on gestation day 28 (term pregnancy: 31–32
ays) were injected with lipopolysaccharide (LPS, 20g/kg) along
he length of the uterus between the fetuses. Following mater-
al LPS exposure, positron emission tomography imaging of the
icroglia-speciﬁc tracer [(11)C]-(R)-PK11195 in one-day old pups
emonstrated an increased number of activated microglia, which
as associated with the severity of motor deﬁcits in the neona-
al rabbit [47]. In midgestation fetal sheep, an age which is similar
n brain development to the preterm human, a single intravenous
i.v.) injection of a low dose of LPS (100ng/kg) resulted in white
atter injury and an increase in number of microglia, both in the
etal forebrain and cerebellum [48,49]. The injurywas further char-
cterized by impaired maturation of electroencephalogram and
elayed cortical development [50] and a reduction in general sys-
emic metabolism of the fetus [51]. Also following administration
f repeated high doses of LPS (1g/kg) [52] or low-dose LPS infu-
ion (100ng, i.v. over 24h, followed by 250ng/24h for 4 days)
53] to fetal sheep there was an increased number of microglia
nd systemic IL-6 or brain TNF--positive cells in the periventric-
lar white matter. Chronic intra-amniotic administration of LPS
for 28d) caused a moderate to extensive activation/inﬁltration
f microglia/macrophages in the subcortical white matter in six
f eight sheep fetuses [54]. Similarly, LPS administered into the
terine artery of late gestation pregnant sheep showed fetal
icroglial activation and macrophage inﬁltration. Importantly, no
PS could be detected in the fetus suggesting that neuroinﬂam-
ation occurred without direct fetal exposure to endotoxin [55].
epeated neonatal exposure to innate immune mediators [56], or
peciﬁc cytokines [57], also results in white matter damage in the
eveloping rodent brain when given at an age corresponding to
he preterm human infant [58–60]. Furthermore, non-infectious
nsults, such as fetal asphyxia, induced by umbilical cord occlusion
48], or cerebral hypoxia–ischemia [61] inmidgestation fetal sheep
esult in marked microglia activation. In neonatal HI, activated
icroglia are themain producers of pro-inﬂammatory IL-18,which
s activated by caspase-1, which is also expressed by microglia.
ndeed, both IL-18 [62] and caspase-1 [63] gene deletion reduces
rain injury giving further support to the concept that microglia
xert toxic effects under such conditions. Thus, similar to evidence
rom human post-mortem studies, reactive microglia responses in
erebral white matter and subcortical brain regions are common
eatures in preterm animal models following both infectious and
on-infectious insults.
. Combination of systemic inﬂammation and
ypoxia–ischemia
There is considerable evidence that LPS-induced systemic
nﬂammation can exacerbate the neuroinﬂammatory response and
rain injury to cerebral hypoxia–ischemia [64] and excitotoxic-
ty [65]. The LPS effects are dependent on the innate immune
eceptor TLR-4 [66] and the adaptor protein myeloid differentia-
ion factor 88 (MyD88) [67]. Stimulation of other innate immune
eceptors also has the capacity to exacerbate hypoxic–ischemic
njury. We showed that giving the viral mimic, poly inosinic:poly
ytidylic acid (Poly I:C), a synthetic ligand for TLR-3, increased
nfarct volume and reduced white matter in neonatal mice [68].
nterestingly, enhanced injury was associated with a decrease in
eparative M2-like CD11b+ microglia, while there was no changeToxicology 48 (2014) 106–112
in M1-polarized cells. Thus, experimental data propose that trigg-
ering innate immune responses systemically may affect both
the intensity and characteristics of neuroinﬂammation. Although
the precise underlying mechanisms remain unclear, inhibition of
TNF- [69] and IL-1 [70], the use of anti-nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-B) peptides [71]
and immune regulatory peptides [72] alleviate LPS-sensitization
of hypoxic–ischemic brain injury, suggesting that inﬂammatory
pathways are important.
9. Microglia in vitro
Whilst there are some criticism over how comparable in vitro
preparations ofmicroglia are to the in vivo situation [73,74], in vitro
studies have allowed for the intimate exploration of key activation
and signaling pathways, and the ability to explore the interaction
between cell types. Organotypic slice cultures from the hippocam-
pus and cortex have also been utilized to investigate the function
of microglia, the beneﬁts of which are better preservation of
brain cytoarchitecture, which allows for examining interactions of
microglia with neurons and glia following injury [75–77].
When interpreting ﬁndings from in vitro studies it is important
to consider which type of cell preparation has been used as there
are differences in responses between cell lines (such as BV2 and
N9, both of murine origin) and primary cultures [78–80]. It is also
important tobe awareof the age atwhichmicroglia for primary cul-
tures are isolated; protocols range from embryonic (E18), neonatal
(postnatal day (P0) to P4), adult (10 weeks) to aged (15 months
old), where differences in reactivity, morphology and functionality
have been observed [80,81]. The use of neonatal brains (P0–P4) is
by far the most common and Lai et al. [81] found these to be the
most reactive in culture in comparison to different ages. It has also
been noted that primary microglia cultures obtained from rats are
more sensitive to TLR-3/4 stimulation than compared to mice [82].
Numerous agents and pathological conditions have been used to
investigate microglial activation and potential for toxicity ranging
from bacteria (LPS), cytokines and chemokines (interferon (IFN)-,
IL-6), proteins, neurotransmitters, reactive oxygen species.
10. Activation states of microglia
Microglia are known to have both beneﬁcial and detrimen-
tal actions, and in recent years numerous studies have focused
on understanding their activation patterns, for detailed reviews
see [73,83–85]. Brieﬂy, microglial activation states have been
sub-classiﬁed into classical activation (M1– tissuedefense andpro-
inﬂammatory cytokine production), alternative activation (M2a
– tissue repair and anti-inﬂammatory cytokine production) and
acquired deactivation (M2b – immunosuppression). Traditionally
LPS has been used to induce robust activation of microglia which
leads to the production of TNF-, inducible nitric oxide (iNOS)
and pro-inﬂammatory cytokines which are all suggested to have
cytotoxic downstream effects, characteristic of an M1 phenotype
[86,87]. IL-4 stimulated microglia upregulate genes and proteins
that characterize an M2a, reparative phenotype [87].
11. Microglial contribution to the pathogenesis of preterm
brain injury
11.1. Reactive oxygen species and microgliaThe immature brain is vulnerable to oxidative stress; and reac-
tive oxygen species (ROS; superoxide (O2−), hydrogen peroxide
(H2O2)) and reactive nitrogen species (RNS; nitric oxide (NO),
peroxynitrite (ONOO−)) are produced by and can act to regulate
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icroglia. LPS + IFN- stimulated microglia produce NO in a time
ependent manner [88]. In vitro imaging studies have also shown
hat in NO producing microglia, O2− is a rate-limiting factor in the
ormation of ONOO− [88]. It has been shown that microglia stimu-
atedwitheither continuousorbolusH2O2 results in theproduction
f nitrite, ROS and mitochondrial O2−. Continuous low H2O2 also
eads to signiﬁcant production of pro-inﬂammatory cytokine IL-
5, and chemokines (e.g. granulocyte colony-stimulating factor,
acrophage inﬂammatory protein-1 and macrophage inﬂam-
atory protein 2-alph) [89]. Activated microglia production of
ntracellular and extracellular ROS is dependent on nicotinamide
denine dinucleotide phosphate (NADPH) oxidase (NOX) [90–92].
or a detailed review see [93,94]. Numerous NOX isoforms exist
n microglia, but it has been shown that LPS stimulated microglia
ctivate NOX1 and NOX2, which is required for the production
f O2−, NO and iNOS, whilst only NOX1 appears to promote IL-
 production [95]. The activity of NOX1, NOX2 and NOX4 can
lso be modulated by GABA, glutamate and ATP stimulation, which
onsequently leads toO2− formation, but not iNOSproduction.Glu-
amatemediated activation of NOX also contributes to a neurotoxic
henotype in microglia [96].
1.2. Excitotoxicity and microglia
Microglia contain purinergic receptors, speciﬁcally P1 and P2
eceptors, which are activated by adenosine and ATP respectively
81,96–98]. Importantly, the P2X7 receptor (P2X7R; an ionotropic
eceptor) and ATP binding cassette (ABC) transporters are required
or microglial IL-1 production [99]. Haynes et al. [100] found that
he metabotropic receptor, P2Y12, is required for the ﬁne move-
ent ofmicroglial processes, therebybeing important in regulating
icroglial activation. Extracellular ATP can activate microglia
nducing chemotaxis and production of superoxide, nitrate, NOX
soforms, TNF- and more ATP [81,96,101,102].
Numerous glutamate receptors are present and func-
ional on microglia, including group I, II and III metabotropic
lutamate (mGlu) receptors, -amino-3-hydroxy-5-methyl-4-
soxazolepropionic acid-kainate (AMPA-KA) and NMDA receptors
NMDAR) [103–107]. For a detailed review about neurotransmit-
ers andmicroglia see [108]. Upon stimulation of AMPA-KA,mGlu2
nd NMDAR microglia are activated and robustly induce TNF-
roduction [103,104,107]. NMDA treatment has also shown to
ncrease production of cellular ROS andNO aswell as anti- and pro-
nﬂammatory cytokines [103]. Microglia treated with glutamate or
lutamate receptor agonists increase microglial c-fos expression
109]. Stimulation of mGlu3, mGlu5 and group III mGlu does
ot result in microglial neurotoxicity [104–106]. Inﬂammatory
ctivation of microglia (by LPS) results in the release of glutamate,
his has been shown to be dependent on lipid peroxidation and
OX but not NO or NOS [110]. Takaki et al. [111] showed that
-glutamate (l-Glu) is released from LPS activated microglia, and
hen co-cultured with astrocytes, results in decreased uptake of
-Glu by astrocytes leading to signiﬁcant extracellular l-Glu. Taken
ogether these factors contribute to increased excitotoxicity that
an be damaging to neurons and oligodendrocytes.
2. Microglial toxicity – effect on oligodendrocytes,
eurons and the blood–brain barrier
2.1. Microglia and oligodendrocytesZajicek et al. [112] investigated the in vitro interactions between
ligodendrocytes and microglia and found that unstimulated
icroglia have minimal contact with oligodendrocytes. However,
ncreased contact was observed following microglial stimulationToxicology 48 (2014) 106–112 109
with IFN-, or LPS + IFN-. Microglial secreted TNF and NO con-
tributed to inducing oligodendrocyte cell death [112,113].
Miller et al. [114] compared the response of LPS (10ng/ml) acti-
vatedmicroglia in co-culturewith oligodendrocyte progenitor cells
(OPCs; immature, neural/glial antigen 2 (NG2)+ and A2B5+) and
oligodendrocytes (mature, galactocerebroside (GalC)+ and myelin
basic protein (MBP)+). LPS activated microglia decreased OPC sur-
vival, in contrast resting and activated microglia increased the
survival of oligodendrocytes. Domercq et al. [115] found microglia
stimulated with a higher dose of LPS (100ng/ml) inhibited
oligodendrocyte glutamate transporters, leading to increased
extracellular glutamate and oligodendrocyte (GalC+ and O1+)
death.
Microglia co-cultured with pre-oligodendrocytes (preOL;
A2B5+, O4+) stimulated with LPS leads to increased preOL apopto-
sis [116,117]. Li et al. [117] found this was mediated by microglial
production of NO and ONOO−. PreOLs and preOL-astrocyte co-
cultures stimulated with LPS do not result in preOL cell death,
highlighting the toxic role of activated microglia. Interestingly, in
mixed glial cultures (microglia, preOLs and astrocytes) exposed
to LPS, NO is not required for toxicity, rather, in the presence of
astrocytes TNF- production was important for mediating preOL
cell death [118].
12.2. Microglia and neurons
Neurons have been shown to activate microglia in co-culture
[119]. Oxygen glucose deprivation (OGD) stressed cortical neurons
activated microglia, which was mediated through extracellular
glutamate binding to mGluRII and NF-B [120], these activated
microglia then further elicitedneurotoxic effects onneurons,which
involved mGluRII, NMDAR, NF-B and TNF- [103,120]. Lai and
Todd [121] also found that culture media from mildly injured neu-
rons induced microglial production of IL-1, TNF- and NO, this
was due to neuronal production of glutamate and ATP. Expos-
ing neuronal cultures to conditioned media from LPS activated
microglia induced severe synapse loss, activated caspase-3 activity,
DNA fragmentation and neuronal cell death, which was mediated
by theMyD88 pathway [87,122,123]. Increased neuronal cell death
was also seen when neurons were exposed to conditioned media
from NMDA treated and mGlu2 stimulated microglia [103,104].
Studies utilizing microglia-neuron co-cultures have further high-
lighted the contribution ofmicroglia to neuronotoxicity. Activating
microglia with IFN- or LPS in co-culture with neurons results in
increased neuronal cell death, suggested to be mediated through
NO production [124]. ATP stimulated microglia also elicit neuro-
toxic effects on hypoxic neurons [81].
12.3. Microglia and BBB
It has been shown that activated microglia can disrupt and
induce injury to constituents of the blood–brain barrier (BBB).
Sumi et al. [125] found that co-culturing rat brain endothelial cells
with microglia and subsequently stimulating with LPS (10ng/ml),
resulted in fragmented tight junctional immunostaining (zona
occludin-1, claudin-5 and occludin), decreased transendothelial
resistance and increased sodium-ﬂuorescein permeability, sug-
gesting increased paracellular transport. This was shown to occur
viaNOXmechanisms. Following OGD and reperfusion, the addition
of microglia to endothelial cell and astrocyte co-cultures, resulted
in increased cell death of endothelial cells. OGD and reperfusion
also resulted in increasedproductionof superoxide andH2O2 [126].
Whether activated microglia inﬂuence pericyte morphology or
function has yet to be determined.
In summary, there is considerable evidence to suggest that
activation of microglia can be neurotoxic and contribute to
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euroinﬂammation seen in the injured preterm brain. However,
icroglia alsomediate critically important functionsduringnormal
rain development. To better understand the injurious versus pro-
ective functions of neuroinﬂammation, microglia activation states
nd the possibility of contribution of systemic immune cells in
reterm brain pathology need to be determined.
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